Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03600818
Registration number
NCT03600818
Ethics application status
Date submitted
17/07/2018
Date registered
26/07/2018
Titles & IDs
Public title
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Query!
Secondary ID [1]
0
0
2017-002989-42
Query!
Secondary ID [2]
0
0
EFC15160
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Polymyalgia Rheumatica
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sarilumab SAR153191 (REGN88)
Treatment: Drugs - Sarilumab-matching placebo
Treatment: Drugs - Prednisone
Treatment: Drugs - Prednisone-matching placebo
Treatment: Drugs - Prednisone
Placebo comparator: Placebo+52 Week Taper - Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
Experimental: Sarilumab 200mg q2w+14 Week Taper - Participants received sarilumab 200 milligrams (mg) as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 14 weeks and prednisone-matching placebo from Week 14 up to Week 52.
Treatment: Drugs: Sarilumab SAR153191 (REGN88)
Pharmaceutical form:solution for injection Route of administration: subcutaneous
Treatment: Drugs: Sarilumab-matching placebo
Pharmaceutical form:solution for injection Route of administration: subcutaneous
Treatment: Drugs: Prednisone
Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Treatment: Drugs: Prednisone-matching placebo
Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Treatment: Drugs: Prednisone
Pharmaceutical form:tablets Route of administration: oral administration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving Sustained Remission at Week 52
Query!
Assessment method [1]
0
0
Sustained remission was defined as meeting all of the following parameters: achievement of disease remission (defined as resolution of signs and symptoms of polymyalgia rheumatica \[PMR\], and normalization of C-reactive protein \[CRP\] {less than \[\<\]10 milligrams per liter \[mg/L\]}) not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active PMR plus an increase in corticosteroid \[CS\] dose due to PMR or elevation of erythrocyte sedimentation rate \[ESR\] attributable to active PMR plus an increase in CS dose due to PMR) from Week 12 through Week 52, sustained reduction of CRP (to \<10 mg/L, with absence of successive elevations to greater than or equal to \[\>=\]10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52.
Query!
Timepoint [1]
0
0
At Week 52
Query!
Secondary outcome [1]
0
0
Total Cumulative Corticosteroid Dose
Query!
Assessment method [1]
0
0
Cumulative dose of CS used for PMR disease was defined as the dose taken up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone (an excess of \<=100 mg of prednisone during the study treatment period). The total cumulative CS dose was based on the total number of days with complete or partial intake, no imputation was done on missed tablets.
Query!
Timepoint [1]
0
0
Up to Week 52
Query!
Secondary outcome [2]
0
0
Number of Participants Who Achieved Disease Remission up to Week 12
Query!
Assessment method [2]
0
0
Disease remission was defined as resolution of signs and symptoms of PMR, and normalization of CRP (\< 10 mg/L). The status of normalization of CRP (\<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was \<10 mg/L, then it was considered as normalization of CRP. Participants who took rescue CS due to active PMR prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12. During the initial 12 weeks of prednisone taper, treatment for one flare before Week 12 was permitted if it was successfully treated with a low dose (\<=5 mg/day) prednisone add-on taper regimen (completed prior to Week 12) and provided that all other sustained remission parameters were met.
Query!
Timepoint [2]
0
0
Up to Week 12
Query!
Secondary outcome [3]
0
0
Number of Participants With Absence of Disease Flare From Week 12 Through Week 52
Query!
Assessment method [3]
0
0
Disease flare was defined as either recurrence of signs and symptoms attributable to active PMR plus an increase in CS dose due to PMR, or elevation of ESR attributable to active PMR plus an increase in CS dose due to PMR.
Query!
Timepoint [3]
0
0
From Week 12 Through Week 52
Query!
Secondary outcome [4]
0
0
Number of Participants With Sustained Reduction of CRP From Week 12 Through Week 52
Query!
Assessment method [4]
0
0
Normalization (sustained reduction) of CRP was defined as CRP levels \<10 mg/L. If there were two or more consecutive visits with CRP \>=10 mg/L, then it was categorized as no normalization of CRP.
Query!
Timepoint [4]
0
0
From Week 12 through Week 52
Query!
Secondary outcome [5]
0
0
Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52
Query!
Assessment method [5]
0
0
Successful adherence to the prednisone taper from Week 12 through Week 52 was defined as participants who did not take rescue therapy from Week 12 through Week 52 and any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of \<=100 mg (or equivalent), such as those employed to manage adverse event (AE) not related to PMR.
Query!
Timepoint [5]
0
0
From Week 12 through Week 52
Query!
Secondary outcome [6]
0
0
Time to First Polymyalgia Rheumatica Flare After Clinical Remission up to Week 52
Query!
Assessment method [6]
0
0
Time to first PMR flare was defined as the duration (in days) from randomization to first PMR flare after clinical remission (defined as resolution of signs and symptoms and normalization of CRP \[\<10 mg/L\]) and up to 52 weeks. Disease flare was defined as either the recurrence of signs or symptoms attributable to active plus an increase in CS dose due to PMR or elevation of ESR attributable to active PMR plus an increase in CS dose due to PMR. Kaplan-Meier method was used for the analysis. Participants who never achieved remission were censored at randomization day; and those who achieved clinical remission and never flared were censored at the end of treatment assessment date up to Week 52.
Query!
Timepoint [6]
0
0
Up to Week 52
Query!
Secondary outcome [7]
0
0
Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 52
Query!
Assessment method [7]
0
0
GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: C-GTI and Specific List. C-GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. C-GTI score was sum of 9 domain-specific scores at each visit and Cumulative GTI score was sum of C-GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 52 are reported in this outcome measure. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. Negative scores reflect improvement in CS toxicities present from Baseline. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, minimum score implies least toxicity and maximum score implies most toxicity.
Query!
Timepoint [7]
0
0
At Week 52
Query!
Secondary outcome [8]
0
0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Query!
Assessment method [8]
0
0
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) to the last dose of the IMP +60 days).
Query!
Timepoint [8]
0
0
From first dose (i.e. Day 1) up to 60 days after last dose date of study drug (i.e. up to Week 60)
Query!
Secondary outcome [9]
0
0
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During TEAE Period
Query!
Assessment method [9]
0
0
Criteria for potentially clinically significant vital sign abnormalities:
Systolic Blood Pressure (SBP): \<= 95 mmHg and decrease from baseline (DFB) more than or equal to (\>=) 20 mmHg; \>= 160 mmHg and increase from baseline (IFB) \>= 20 mmHg
Diastolic blood pressure (DBP): \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg.
Heart Rate (HR): \<= 50 beats per min (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>= 20 bpm
Weight: \>=5% DFB; \>=5% IFB.
TEAE period was defined as the time from the first dose of the IMP to the last dose of the IMP + 60 days.
Query!
Timepoint [9]
0
0
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
Query!
Secondary outcome [10]
0
0
Number of Participants With Potentially Clinically Significant Abnormalities - Hematological Parameter
Query!
Assessment method [10]
0
0
Criteria for potentially clinically significant laboratory abnormalities included:
Hemoglobin (Hb): \<= 115 grams per liter (g/L) (Male \[M\]), \<= 95 g/L (Female \[F\]); \>= 185 g/L (M), \>= 165 g/L (F); DFB \>= 20 g/L .
Hematocrit: \<= 0.37 volume/volume (v/v) (M); \<= 0.32 v/v (F); \>= 0.55 v/v (M); \>= 0.5 v/v (F).
Erythrocytes: \>=6 Tera/ liter (L).
Platelets: \< 100 Giga/L, \>= 700 Giga/L.
Leukocytes: \< 3.0 Giga/L (Non-Black \[NB\]); \< 2.0 Giga/L (Black \[B\]), \>= 16.0 Giga/L.
Neutrophils: \< 1.5 Giga/L (NB); \< 1.0 Giga/L (B).
Lymphocytes: \> 4.0 Giga/L.
Monocytes: \> 0.7 Giga/L.
Basophils: \> 0.1 Giga/L.
Eosinophils: \> 0.5 Giga/L or \> upper limit of normal (ULN) (if ULN \>= 0.5 Giga/L).
Query!
Timepoint [10]
0
0
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
Query!
Secondary outcome [11]
0
0
Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters
Query!
Assessment method [11]
0
0
Criteria for potentially clinically significant abnormalities:
Glucose: \<=3.9 millimoles (mmol)/L and \< lower limit of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]); \>=7 mmol/L (fasted \[fas\]).
HbA1c: \>8%.
Cholesterol: \>=7.74 mmol/L.
Triglycerides: \>=4.6 mmol/L.
C Reactive Protein (CRP): \>2 ULN or \>10 mg/L (if ULN not provided).
Query!
Timepoint [11]
0
0
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
Query!
Secondary outcome [12]
0
0
Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function
Query!
Assessment method [12]
0
0
Criteria for potentially clinically significant abnormalities:
Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline.
Creatinine clearance: \>=60 to \<90 milliliters per minute (mL/min); \>=30 to \<60 mL/min ; \>=15 to \<30 mL/min; \<15 mL/min.
Blood urea nitrogen: \>=17 mmol/L.
Urate: \<120 micromol/L; \>408 micromol/L.
Query!
Timepoint [12]
0
0
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
Query!
Secondary outcome [13]
0
0
Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function
Query!
Assessment method [13]
0
0
Criteria for potentially clinically significant abnormalities:
Albumin: \<= 25 g/L.
Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN.
Aspartate Aminotransferase (AST): \>3 ULN; \>5 ULN; \>10 ULN; \>20 ULN.
Alkaline Phosphatase: \>1.5 ULN.
Bilirubin: \>1.5 ULN; \>2 ULN.
ALT and Total Bilirubin: ALT \> 3 ULN and Bilirubin \> 2 ULN
Query!
Timepoint [13]
0
0
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
Query!
Secondary outcome [14]
0
0
Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) Response
Query!
Assessment method [14]
0
0
ADA response categories: 1) Treatment-boosted ADA positive participant: Participant with a positive ADA assay response at Baseline and with at least a 4-fold increase in titer compared to Baseline during TEAE period. 2) Treatment-emergent ADA positive participant: Participant with non-positive assay (meaning negative or missing) response at Baseline but with a positive assay response during the TEAE period (defined as the time from the first dose of the IMP to the last dose of the IMP +60 days).
Query!
Timepoint [14]
0
0
From first dose (i.e., Day 1) up to 60 days after last dose date of study drug (i.e., up to Week 60)
Query!
Secondary outcome [15]
0
0
Pharmacokinetics (PK): Serum Trough Concentration (Ctrough) of Sarilumab
Query!
Assessment method [15]
0
0
Ctrough was pre dose concentration of drug. Data for this outcome measure was not planned to be collected and analyzed for placebo arm (Placebo+52 Week Taper) as pre-specified in the protocol.
Query!
Timepoint [15]
0
0
Pre-dose on Week 0 (Baseline), Week 2, 4, 12, 16, 24, and 52
Query!
Secondary outcome [16]
0
0
Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24
Query!
Assessment method [16]
0
0
Serum concentrations of functional sarilumab were analyzed using validated enzyme linked immunosorbent assay.
Query!
Timepoint [16]
0
0
Post-dose at Week 24
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
* Diagnosis of PMR according to European League Against Rheumatism/American College of Rheumatology classification criteria.
* Participants must be on prednisone of at least 7.5 milligrams per day (mg/day) (or equivalent) and not exceeding 20 mg/day at screening and during the screening period.
* Participant was willing and able to take prednisone of 15 mg/day at randomization.
* Participants had a history of being treated for at least 8 weeks with prednisone (greater than or equal to [>=]10 mg/day or equivalent).
* Participants must have had at least one episode of unequivocal PMR flare while attempting to taper prednisone at a dose that was >= 7.5 mg/day (or equivalent) within the past 12 Weeks prior to screening:
* Unequivocal symptoms of PMR flare included shoulder and/or hip girdle pain associated with inflammatory stiffness.
* Participants had erythrocyte sedimentation rate >=30 millimeters per hour (mm/hr) and/or C-reactive protein >=10 milligrams per liter (mg/L) associated with PMR disease activity within 12 weeks prior to screening.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* Diagnosis of giant cell arteritis (e.g., persistent or recurrent localized headache, temporal artery or scalp tenderness, jaw claudication, extremity claudication, blurry or loss of vision, symptoms of stroke).
* Diagnosis of active fibromyalgia.
* Concurrent rheumatoid arthritis or other inflammatory arthritis or other connective tissue diseases, such as but not limited to systemic lupus erythematosus, systemic sclerosis, vasculitis, myositis, mixed connective tissue disease, and ankylosing spondylitis.
* Concurrent diagnosis of rhabdomyolysis or neuropathic muscular diseases.
* Inadequately treated hypothyroidism.
* Organ transplant recipient.
* Therapeutic failure including inadequate response or intolerance, or contraindication, to biological interleukin-6 antagonist.
* Any prior (within the defined period below) or concurrent use of immunosuppressive therapies but not limited to any of the following:
* Janus kinase inhibitor within 4 weeks of Baseline.
* Alkylating agents including cyclophosphamide within 6 months of Baseline.
* Cell-depletion agents (e.g., anti CD20) without evidence of recovery of B cells to Baseline level.
* Tumor necrosis factor inhibitors within 2-8 weeks (etanercept within 2 weeks, infliximab, certolizumab, golimumab, or adalimumab within 8 weeks), or after at least 5 half-lives have elapsed, whichever was longer.
* Abatacept within 8 weeks of Baseline.
* Anakinra within 1 week of Baseline.
* Cyclosporine, azathioprine or mycophenolate mofetil or leflunomide within 4 weeks of Baseline.
* Unstable methotrexate (MTX) dose and/or MTX dose greater than (>) 15 mg/week within 3 months of Baseline
* Concurrent use of systemic CS for conditions other than PMR.
* Pregnant or breastfeeding woman.
* Participants with active or untreated latent tuberculosis.
* Participants with history of invasive opportunistic infections.
* Participants with fever associated with infection or chronic, persistent or recurring infections required active treatment.
* Participants with uncontrolled diabetes mellitus.
* Participants with non-healed or healing skin ulcers.
* Participants who received any live, attenuated vaccine within 3 months of Baseline.
* Participants who were positive for hepatitis B, hepatitis C and/or human immunodeficiency virus.
* Participants with a history of active or recurrent herpes zoster.
* Participants with a history of or prior articular or prosthetic joint infection.
* Prior or current history of malignancy.
* Participants who have had surgery within 4 weeks of screening or planned surgery during study.
* Participants with a history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/10/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/05/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
118
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 0360003 - Camberwell
Query!
Recruitment hospital [2]
0
0
Investigational Site Number 0360001 - Kogarah
Query!
Recruitment hospital [3]
0
0
Investigational Site Number 0360002 - Maroochydore
Query!
Recruitment hospital [4]
0
0
Investigational Site Number 0360004 - Woodville South
Query!
Recruitment postcode(s) [1]
0
0
3124 - Camberwell
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville South
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Iowa
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Washington
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Buenos Aires
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Caba
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
San Miguel de Tucuman
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Gent
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Leuven
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Hamilton
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Montreal
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Rimouski
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Sherbrooke
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Trois-Rivières
Query!
Country [20]
0
0
Estonia
Query!
State/province [20]
0
0
Tallinn
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Brest Cedex
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Caen Cedex 9
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Le Kremlin Bicetre
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Lille Cedex
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Montivilliers
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Montpellier
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Paris
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Pierre Benite Cedex
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Toulouse Cedex 09
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Bad Abbach
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Berlin
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Dresden
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Kirchheim Unter Teck
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
München
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Tübingen
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Debrecen
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Haifa
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Kfar Saba
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Petah-Tikva
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Tel Hashomer
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Milano
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Pisa
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Reggio Emilia
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Rozzano
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Verona
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Fuchu-Shi
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Kamakura-Shi
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Kawachinagano-Shi
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Takasaki-Shi
Query!
Country [50]
0
0
Netherlands
Query!
State/province [50]
0
0
Alkmaar
Query!
Country [51]
0
0
Netherlands
Query!
State/province [51]
0
0
Almelo
Query!
Country [52]
0
0
Netherlands
Query!
State/province [52]
0
0
Den Haag
Query!
Country [53]
0
0
Netherlands
Query!
State/province [53]
0
0
Leeuwarden
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Nijmegen
Query!
Country [55]
0
0
Netherlands
Query!
State/province [55]
0
0
Rotterdam
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Moscow
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Saint-Petersburg
Query!
Country [58]
0
0
Spain
Query!
State/province [58]
0
0
A Coruña / Santiago De Compostela
Query!
Country [59]
0
0
Spain
Query!
State/province [59]
0
0
Badalona
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Getafe
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Granada
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Madrid
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Santander
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Valencia
Query!
Country [65]
0
0
Switzerland
Query!
State/province [65]
0
0
Bern
Query!
Country [66]
0
0
Switzerland
Query!
State/province [66]
0
0
St. Gallen
Query!
Country [67]
0
0
United Kingdom
Query!
State/province [67]
0
0
Gateshead
Query!
Country [68]
0
0
United Kingdom
Query!
State/province [68]
0
0
Leeds
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
Manchester
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Newport
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
Plymouth
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Southend
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Regeneron Pharmaceuticals
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective: To evaluate the efficacy of KEVZARA (sarilumab) in participants with polymyalgia rheumatica (PMR) as assessed by the proportion of participants with sustained remission for sarilumab with a shorter corticosteroid (CS) tapering regimen as compared to placebo with a longer CS tapering regimen. Secondary Objectives: * To demonstrate the efficacy of sarilumab in participants with PMR compared to placebo, in combination with a CS taper with regards to: * Clinical responses (such as components of sustained remission, disease remission rates, time to first disease flare) over time. * Cumulative CS (including prednisone) exposure. * To assess the safety (including immunogenicity) and tolerability of sarilumab in participants with PMR. * To measure sarilumab serum concentrations in participants with PMR. * To assess the effect of sarilumab in reducing glucocorticoid toxicity as measured by the composite glucocorticoid toxicity index (GTI) questionnaire.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03600818
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/18/NCT03600818/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/18/NCT03600818/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03600818